Many animals use venoms for self-defense or hunting. The components of such venom, known as toxins, interfere with various physiological processes – which is also the reason why they are so interesting for the development of new pharmacological agents.
Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer
In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab
September 13, 2024